12hon MSN
Pelthos signals continued ZELSUVMI momentum and targets expanded product launches through 2027
Q4 2025 Management View Scott Plesha, CEO, stated that Pelthos made “great progress” in three key areas: ZELSUVMI’s “substantial demand-generated revenue growth” following its Q3 launch, the ...
Ligand Pharmaceuticals announced that its partner, Pelthos Therapeutics, has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum, ...
Pelthos is set to launch ZELSUVMI™, the first and only home-administered prescription treatment for Molluscum contagiosum, addressing a significant unmet need. The successful merger has raised $50.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results